Dr Anthony Stein speaks to ecancer about overcoming immune resistance in HR-MDS: A detailed safety and efficacy phase II data on bexmarilimab.

This study explores a new treatment for patients with relapse refractory myelodysplasia using a Clever-1 antibody bexmarilimab combined with azacitidine.

This approach converts anti-tumorogenic macrophages to pro-inflammatory types, enhancing T cell response.

In the frontline high-risk group, 21 patients showed a 55% overall response rate.

The relapsed refractory group had a 47% response rate. A phase three study is planned to further evaluate this combination therapy.